The shadow of generic rivalry has consistently loomed over copyright’s blockbuster drug, Sildenafil, triggering questions about the outlook of connected drug stakes. While initial years saw substantial profits, the intellectual property end has opened the path for cheaper copies, possibly lowering earnings and presenting a real danger for investo